How a Simple Blood Test Could Transform Colorectal Cancer Screening

Colorectal cancer is among the most common cancers in Australia, yet many cases can be prevented or treated successfully when detected early. Screening can identify cancer before symptoms appear, or find precancerous bowel polyps that can be removed before they become dangerous.

The standard options are effective, but participation remains uneven. Home-based faecal immunochemical tests (FIT) are convenient and look for hidden blood in stool, while colonoscopy provides a detailed examination of the bowel and allows clinicians to remove suspicious growths. Some people avoid screening because of embarrassment, inconvenience, anxiety, or difficulty completing the test.

A blood-based screening test could offer a less confronting first step. Researchers are investigating whether molecules released by colorectal tumours into the bloodstream can reveal disease early, potentially making routine screening easier to access. The promise is considerable, but the test must prove that it can detect cancer accurately and improve outcomes in real healthcare settings.

Why Screening Needs New Tools

Colorectal cancer can develop gradually from abnormal cells or adenomatous polyps. Early disease may cause no obvious symptoms, meaning people can feel well while changes are occurring in the bowel. By the time symptoms such as persistent bleeding, altered bowel habits, unexplained weight loss, or iron-deficiency anaemia appear, the disease may be more advanced.

Screening programs are designed to reach people before symptoms emerge. However, even a well-established program depends on participation, follow-up, and timely access to diagnostic procedures. A test that requires only a blood sample could fit naturally into a general practice appointment or another routine health check, especially for people who do not complete a stool-based kit.

That convenience would matter most if it helped close gaps in screening participation. A blood draw is not automatically better than FIT or colonoscopy, but it may be acceptable to people who currently avoid those options. Its value would come from combining ease of use with dependable clinical performance.

How Blood-Based Screening Works

Several technologies are being studied for colorectal cancer detection. Circulating tumour DNA, or ctDNA, consists of small fragments of genetic material shed by cancer cells into the bloodstream. Researchers may look for mutations, abnormal DNA methylation patterns, or other molecular signatures associated with bowel cancer.

Other approaches examine circulating proteins, RNA, metabolites, or combinations of biological markers. A multi-marker assay may identify signals that are too subtle for a single measurement. Some tests use machine-learning models to combine these signals with age, sex, symptoms, and other clinical information.

The central challenge is signal strength. Early tumours may release very little detectable material, and benign conditions can create overlapping biological patterns. A useful blood test therefore needs carefully designed laboratory methods, large validation studies, and clear thresholds for positive and negative results.

What Early Evidence Shows

Initial studies suggest that blood-based tests can detect a meaningful proportion of colorectal cancers, particularly when disease is more advanced. That is encouraging because it demonstrates that tumours can leave measurable traces in circulation. However, screening requires strong performance in people who feel healthy, including those with early-stage cancers and precancerous lesions.

Sensitivity measures how often a test identifies disease when it is present. Specificity measures how often it correctly reassures people who do not have disease. A test with low specificity could produce many false-positive results, leading to anxiety and unnecessary colonoscopies. A test with low sensitivity could provide false reassurance and delay diagnosis.

Researchers must also establish whether blood testing reduces late-stage diagnoses and deaths, rather than simply finding cancers in a research setting. Long-term studies will need to assess participation, repeat testing, follow-up colonoscopy, health equity, costs, and outcomes across different communities.

From Laboratory Discovery To Patient Care

A promising assay must pass through several stages before it can become part of standard screening. Laboratory researchers first identify candidate biomarkers, then test them in carefully selected samples. Independent studies must confirm that the results remain accurate across laboratories, age groups, ethnic backgrounds, medical conditions, and risk levels.

Implementation is equally important. A positive blood test would usually need referral for diagnostic colonoscopy, so healthcare services would need enough capacity to manage additional demand. Systems would also require secure reporting, reminders, clinical guidelines, and processes that prevent people from being lost between an abnormal result and follow-up care.

This is where research translation becomes practical. The Brisbane Diamantina network connects researchers, universities, and health services to support the movement of evidence into care. Its work reflects the broader principle that a new screening technology succeeds only when laboratory science, clinical expertise, public health planning, and patient experience are considered together.

The Role Of General Practice

General practitioners could become an important access point for blood-based colorectal cancer screening. A GP may identify whether a person is due for screening, explain the benefits and limitations of available options, check for symptoms that require diagnostic assessment, and arrange follow-up when results are abnormal.

Research translation in primary care also involves workflow. A test that takes only minutes to collect may still fail if results are difficult to interpret, billing arrangements are unclear, or clinicians lack a reliable referral pathway. Guidance on translating chronic disease research illustrates why evidence must be adapted to everyday consultations rather than simply published.

Patients should also understand the difference between screening and diagnosis. People with rectal bleeding, persistent bowel changes, unexplained anaemia, or a strong family history may require a clinician-led assessment regardless of a blood test result. A negative screening result cannot rule out every bowel condition.

Practical Priorities For Safe Adoption

Before a blood test becomes a routine option, health services and researchers should focus on:

• Proving reliable detection of early-stage colorectal cancer and significant precancerous lesions.
• Comparing performance directly with FIT and assessing which approach achieves higher participation.
• Creating rapid, affordable pathways for colonoscopy after a positive result.
• Testing the assay across diverse populations, including rural, remote, culturally diverse, and disadvantaged communities.
• Providing plain-language information about false positives, false negatives, privacy, and follow-up.

Public confidence will depend on transparent evidence. People need to know what the test can detect, what it cannot detect, and what happens next. Clear communication can prevent both exaggerated expectations and unnecessary fear.

Equity should be measured from the beginning rather than added later. If a blood test is available only through private clinics or requires costly out-of-pocket payments, it may widen existing gaps. A successful screening pathway should make participation easier for people who face transport, language, disability, work, or healthcare access barriers.

The Evidence Still Has To Mature

A simple blood draw could make colorectal cancer screening more acceptable and easier to integrate into routine care. It could support earlier detection, encourage participation, and offer another pathway for people who do not use existing screening methods. Those benefits, however, depend on accurate testing and dependable follow-up.

The most important question is not whether a test can find cancer in a sample. It is whether offering that test across a population leads to earlier treatment, fewer advanced cancers, and better survival without causing avoidable harm. Answering that question will require collaboration between patients, researchers, clinicians, laboratories, policymakers, and health services.

Follow developments in colorectal cancer research, discuss appropriate screening with a healthcare professional, and support evidence-based programs that make early detection accessible to more Australians.